The stock of Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) hit a new 52-week low and has $11.74 target or 12.00% below today’s $13.34 share price. The 9 months bearish chart indicates high risk for the $108.34M company. The 1-year low was reported on Sep, 30 by Barchart.com. If the $11.74 price target is reached, the company will be worth $13.00 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 60,900 shares traded hands or 42.12% up from the average. Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) has declined 0.59% since February 26, 2016 and is downtrending. It has underperformed by 11.01% the S&P500.
Analysts await Eiger Biopharmaceuticals Inc (EIGR) to report earnings on November, 14. They expect $-1.17 earnings per share, up 71.11% or $2.88 from last year’s $-4.05 per share. After $-1.87 actual earnings per share reported by Eiger Biopharmaceuticals Inc for the previous quarter, Wall Street now forecasts -37.43% EPS growth.
According to Zacks Investment Research, “Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California.”
More notable recent Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) news were published by: Marketwatch.com which released: “Virtual Stock Exchange” on March 24, 2016, also Prnewswire.com with their article: “Eiger BioPharmaceuticals Announces License of Worldwide Rights to Pegylated …” published on April 20, 2016, Prnewswire.com published: “Eiger BioPharmaceuticals to Present at the 2016 Wedbush PacGrow Healthcare …” on August 08, 2016. More interesting news about Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) were released by: Prnewswire.com and their article: “Eiger BioPharmaceuticals to Present at the BioCentury NewsMakers in the …” published on September 06, 2016 as well as Prnewswire.com‘s news article titled: “Eiger BioPharmaceuticals Announces License Agreement with Nippon Kayaku to …” with publication date: November 09, 2015.
EIGR Company Profile
Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, incorporated on February 24, 2012, is a clinical-stage biopharmaceutical company. The Firm is focused on the development and commercialization of products for the treatment of orphan diseases. The Company’s pipeline includes three Phase II candidates addressing over four distinct orphan diseases. The Company’s pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.